Evidence map›Paper›PMID 34050904›Full record

Observational studyJournal of nephrology2021

Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.

Paul Lesny, Mark Anderson, Gavin Cloherty, Michael Stec, Anja Haase-Fielitz, Mathias Haarhaus, Carla Santos, Carlos Lucas, Fernando Macario, Michael Haase

Abstract readLetterMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paul LesnyDiaverum Renal Care Center, 14469, Potsdam, Germany.ORCID 0000-0003-3001-5257
Mark AndersonAbbott Infectious Disease Research, Chicago, IL, 60064-3500, USA.
Gavin ClohertyAbbott Infectious Disease Research, Chicago, IL, 60064-3500, USA.
Michael StecAbbott Infectious Disease Research, Chicago, IL, 60064-3500, USA.
Anja Haase-FielitzBrandenburg Medical School Theodor Fontane, 16816, Neuruppin, Germany.ORCID 0000-0001-6881-2249
Mathias HaarhausDiaverum AB, 21532, Malmö, Sweden.ORCID 0000-0001-8274-6356
Carla SantosDiaverum AB, 21532, Malmö, Sweden.
Carlos LucasDiaverum AB, 21532, Malmö, Sweden.
Fernando MacarioDiaverum AB, 21532, Malmö, Sweden.
Michael HaaseDiaverum Renal Care Center, 14469, Potsdam, Germany. michael.haase@diaverum.com.ORCID 0000-0001-8212-7416

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDialysis patients are at risk for lower SARS-CoV-2-vaccine immunogenicity than the normal population. We assessed immunogenicity to a first mRNA- or vector-based SARS-CoV-2-vaccination dose in dialysis patients.

methodsIn a multicenter observational pilot study, 2 weeks after a first vaccination (BNT162b2/Pfizer-BioNTech [Comirnaty] or ChAdOx1 nCoV-19/Oxford-Astra-Zeneca [Vaxzevria]), hemodialysis patients (N = 23), peritoneal dialysis patients (N = 4) and healthy staff (N = 14) were tested for SARS-CoV-2-spike IgG/IgM, Nucleocapsid-protein-IgG-antibodies and plasma ACE2-receptor-binding-inhibition capacity. Hemodialysis patients who had had prior COVID-19 infection (N = 18) served as controls. Both response to first SARS-CoV-2 vaccination and IgG spike-positivity following prior COVID-19 infection were defined as SARS-CoV-2 spike IgG levels ≥ 50 AU/mL.

resultsVaccination responder rates were 17.4% (4/23) in hemodialysis patients, 100% (4/4) in peritoneal dialysis patients and 57.1% (8/14) in staff (HD vs. PD: p = 0.004, HD vs. staff: p = 0.027). Among hemodialysis patients, type of vaccine (Comirnaty N = 11, Vaxzevria N = 12, 2 responders each) did not appear to influence antibody levels (IgG spike: Comirnaty median 0.0 [1.-3. quartile 0.0-3.8] versus Vaxzevria 4.3 [1.6-20.1] AU/mL, p = 0.079). Of responders to the first dose of SARS-CoV-2 vaccination among hemodialysis patients (N = 4/23), median IgG spike levels and ACE2-receptor-binding-inhibition capacity were lower than that of IgG spike-positive hemodialysis patients with prior COVID-19 infection (13/18, 72.2%): IgG spike: median 222.0, 1.-3. quartile 104.1-721.9 versus median 3794.6, 1.-3. quartile 793.4-9357.9 AU/mL, p = 0.015; ACE2-receptor-binding-inhibition capacity: median 11.5%, 1.-3. quartile 5.0-27.3 versus median 74.8%, 1.-3. quartile 44.9-98.1, p = 0.002.

conclusionsTwo weeks after their first mRNA- or vector-based SARS-CoV-2 vaccination, hemodialysis patients demonstrated lower antibody-related response than peritoneal dialysis patients and healthy staff or unvaccinated hemodialysis patients following prior COVID-19 infection.

Indexed as

COVID-19SARS-CoV-2BNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesHumansPilot ProjectsProspective StudiesRenal DialysisRNA, MessengerVaccinationBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesRNA, MessengerACE2 receptor binding inhibition capacityCOVID-19HemodialysismRNA- or vector-based SARS-CoV-2 vaccinationPeritoneal dialysisResponder

Identifiers

PMID34050904
PMCPMC8164063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.